HRT Financial
MLYS icon

HRT Financial’s Mineralys Therapeutics MLYS Stock Holding History

HRT Financial’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85M Sell
68,565
-27,355
-29% -$751K ﹤0.01% 1801
2026
Q1 		$2.6M Buy
95,920
+58,684
+158% +$1.72M 0.01% 1432
2025
Q4 		$1.35M Sell
37,236
-96,802
-72% -$3.88M ﹤0.01% 1544
2025
Q3 		$5.08M Buy
134,038
+123,961
+1,230% +$2.68M 0.02% 671
2025
Q2 		$136K Buy
+10,077
New +$146K ﹤0.01% 2149

Other funds holding MLYS

Catalys Pacific
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Samsara BioCapital
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Laurion Capital Management
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HRT Financial's MLYS Position: Q2 2026 in Review

HRT Financial reduced its Mineralys Therapeutics (MLYS) stake by 29% in Q2 2026, selling an estimated $751K and leaving 68,565 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1801.

HRT Financial first reported a position in MLYS in Q2 2025 and has held it in 5 quarters since. The position peaked at $5.08M in Q3 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • HRT Financial held 68,565 shares of Mineralys Therapeutics worth $1.85M as of Q2 2026.
  • HRT Financial sold 27,355 Mineralys Therapeutics shares in Q2 2026, an estimated $751K.
  • Mineralys Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #1801 holding.
  • HRT Financial first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • HRT Financial's Mineralys Therapeutics position peaked at $5.08M in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.